Invention Grant
- Patent Title: scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity
-
Application No.: US17713087Application Date: 2022-04-04
-
Publication No.: US11976112B2Publication Date: 2024-05-07
- Inventor: Huawei Qiu , Clark Pan , Julie Bird
- Applicant: GENZYME CORPORATION
- Applicant Address: US MA Cambridge
- Assignee: Genzyme Coporation
- Current Assignee: Genzyme Coporation
- Current Assignee Address: US MA Cambridge
- Agency: Steptoe LLP
- Agent Z. Ying Li; Mauricio Alvarez
- The original application number of the division: US15555499
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/00 ; C07K16/22 ; C07K16/46 ; C12N15/11 ; C12N15/62 ; A61K39/00
Abstract:
An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
Public/Granted literature
- US20220363740A1 SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY Public/Granted day:2022-11-17
Information query
